Advances in Cystic Fibrosis Perspectives From Orlando, 2016

Slides:



Advertisements
Similar presentations
TREATMENT FOR SUPERIMPOSED PSEUDOMONAS AERUGINOSA INFECTION.
Advertisements

BY ELIZABETH LITTLE AND LEAH RAYGO Cystic Fibrosis: The Crisis in Ireland.
Infection Prevention for Cystic Fibrosis Patients Kathy Mathews RN, CIC LPCH Infection Control Department.
Will Fagahan Ryan Iglodi 2A Fuck MArc FUCKING JOE.
Cystic Fibrosis Autosomal recessive Faulty gene causes mucus to build up in lungs, –Become infected Lung damage usually causes early death Treatments:
TIP has a safety and efficacy profile comparable with TIS, and offers a far more convenient treatment option for pseudomonas lung infection in CF. Konstan.
By: Paige Whalen and Alex Ung.  Mutation in the gene called cystic fibrosis transmembrane conductance regulator.  Due to loss of chromosome, located.
Hot Topics in Antibiotic Management of Pediatric CF Lung Disease Mike Tracy, MD Fellow, Pediatric Pulmonary.
Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature.
Introduction. Practical Perspectives in the Surgical Management of Parkinson Disease: LCIG.
Brief History in USA & UK
Research collaboration in CF
Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis* Diana Bilton, MD;
Site, Sponsor, CRO: Understanding Roles & Expectations Creating a Team Approach Alan Genatossio, BSN, RN Seattle Children’s, Seattle, WA Colleen.
Pseudomonas Infection in Cystic Fibrosis
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times  F.B. Spencker, L. Staber, T. Lietz,
Dengue Prevention in Asia
Cost of care and clinical condition in paediatric cystic fibrosis patients  Ulrich Baumann, Christiane Stocklossa, Wolfgang Greiner, Johann-Matthias Graf.
Pseudomonas Lung Infections in Cystic Fibrosis
Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact  C.R. Hansen, T. Pressler, W. Ridderberg, H.K.
REFLECT: First-Line Lenvatinib vs Sorafenib in HCC Study Design
Advances in Cystic Fibrosis 2017
Patient-Centered Care in Cystic Fibrosis
Advances in Cystic Fibrosis Views and Perspectives From Basel, Switzerland, 2016.
Infections in Patients with Cystic Fibrosis
Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.
Evaluating Effects of CFTR Modulation in Cystic Fibrosis
Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients  Helle Krogh Johansen, Samuel.
Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.
Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed.
Advances in Cystic Fibrosis: Perspectives from Phoenix 2015
Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort  Margaret Rosenfeld, Julia Emerson, Sharon McNamara,
Dos and Don’ts for High-Risk Elderly Patients With AF
Cystic Fibrosis Autosomal recessive Faulty gene causes mucus to build up in lungs, Become infected Lung damage usually causes early death Treatments:
New Horizons in Cystic Fibrosis Clinical Developments From Fall 2014
D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M
CAD and HF Often Coexist
A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study  Maret L. Maliniak, Arlene A.
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection 
Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia  P.Ø. Jensen, C. Moser, A. Kharazmi,
A. Oliver, A. Mena  Clinical Microbiology and Infection 
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study  Christine Rønne.
Addressing Treatment Challenges in Cystic Fibrosis
Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn 
Implementation of European standards of care for cystic fibrosis ��� Control and treatment of infection  J.S. Elborn, M. Hodson, C. Bertram  Journal of.
UK Cystic Fibrosis Registry Annual Data Report 2017
Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators
M. C. Alanin, K. G. Nielsen, C. von Buchwald, M. Skov, K. Aanaes, N
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009  Yolanda P. Lillquist,
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis  Sanja Stanojevic, Valerie Waters, Joseph L.
Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI®
Different opinions of physicians on the importance of measures to prevent acquisition of Pseudomonas aeruginosa from the environment  Gratiana Steinkamp,
Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi 
November, 2018 Ljubljana, Slovenia
Eradication of early P. aeruginosa infection in children
Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis  Geraint B. Rogers, Lucas R. Hoffman,
Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.
A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis  Kavi J. Littlewood, Kyoko Higashi,
Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.
Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa  Karen O. McKay, Peter J. Cooper, Peter P. van.
Strategies for Infection Control in Cystic Fibrosis
Design of adult and paediatric studies investigating the efficacy and tolerability of ivacaftor [16, 17]. Design of adult and paediatric studies investigating.
CFTR modulators and pregnancy: Our work has only just begun
Daniel V Schidlow, M.D.  Journal of Cystic Fibrosis 
Patient and Clinician Perspectives on Preventive Therapy for Migraine
Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern? 
B. Martha, D. Croisier, A. Fanton, K. Astruc, L. Piroth, F. Huet, P
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial  Michael W. Konstan, Patrick A. Flume, Matthias.
Journal of Cystic Fibrosis
Presentation transcript:

Advances in Cystic Fibrosis Perspectives From Orlando, 2016

Update on Inhaled Antibiotics

Inhaled Levofloxacin vs Inhaled Tobramycin

Findings

Does Inhaled Aztreonam Affect the CF Lung Microbiome?

Observations

CFTR Modulators in Young Children

Long-Term Safety and Efficacy of Ivacaftor in Children Aged 2 to 5 Years KLIMB

Ivacaftor in Children Aged 2 to 5 Years -- Results

Commentary

Lumacaftor/Ivacaftor in Children Aged 6 to 11 Years

AEs Reported

Lumacaftor/Ivacaftor in Children Aged 6 to 11 Years -- Observations

Patient Education in Preventing Infection

Reducing Transmission of Pseudomonas aeruginosa?

Methods

Face Masks -- Findings

Family Attitudes Toward Infection Control

Commentary

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.